PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nonacog Gamma→

Nonacog Gamma PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~55000 g/mol
Drug class
Recombinant coagulation factor IXantihaemorrhagic biologic
Mechanism of action
Recombinant human factor IX replaces deficient or absent factor IX in the intrinsic coagulation pathway. Activated factor IX, together with activated factor VIII, activates factor X and supports thrombin generation and fibrin clot formation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency), under the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rixubis · https://www.medicines.org.uk/emc/product/11038/smpc

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Nonacog Gamma PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nonacog Gamma Permitted Daily Exposure (PDE) report (the Nonacog Gamma PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nonacog Gamma Occupational Exposure Limit (OEL) report (the Nonacog Gamma OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.